In the long history of great highly acclaimed first to the market products, its always been good for the first one to have a competitor or a worthy opponent, it really helps to stimulate interest and the market thats out there. There will be more HCV meds coming and they will all be expensive, All these big pharma companies want there piece of the $ pie. But all it will take is one of them to give in and reduce there price uncharacteristically and we could see a tumble in price. Let's hope so, but its unlikely.
(Reuters) - European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.
Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday.
Yes! let the competition for patients begin.
In the long history of great highly acclaimed first to the market products, its always been good for the first one to have a competitor or a worthy opponent, it really helps to stimulate interest and the market thats out there. There will be more HCV meds coming and they will all be expensive, All these big pharma companies want there piece of the $ pie. But all it will take is one of them to give in and reduce there price uncharacteristically and we could see a tumble in price. Let's hope so, but its unlikely.
matt
http://www.reuters.com/article/2014/11/21/us-europe-medicine-approvals-idUSKCN0J518920141121
(Reuters) - European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.
Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday.